Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03572478 · ClinicalTrials.gov registry record · Phase 1
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03572478 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 12 participants.
The verdict
NCT03572478, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a phase 1/phase 2a study of the combination of immune checkpoint inhibitor (nivolumab) in combination with the PARP inhibitor (rucaparib) for patients with metastatic castration resistant prostate cancer (mCRPC) and metastatic/recurrent endometrial cancer. In the phase 1 portion, the safety of the combination dosing will be determined. If the combination dosing is determined to be safe and feasible, the study will move onto phase 2a. In the phase 2a portion, participants will be randomized to receive either: rucaparib alone, nivolumab alone, or combination therapy (rucaparib and nivolumab).
Interventions
- DRUG Nivolumab
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03572478
The ClinicalTrials.gov registry entry for NCT03572478 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03572478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03572478 about?
NCT03572478 is a clinical study titled "Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer". This is a phase 1/phase 2a study of the combination of immune checkpoint inhibitor (nivolumab) in combination with the PARP inhibitor (rucaparib) for patients with metastatic castration resistant prostate cancer (mCRPC) and metastatic/recurrent endometrial cancer. In the phase 1 portion, the safety...
What is the current status of trial NCT03572478?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-08-14. Estimated completion is 2020-10-01.
What interventions are being tested in trial NCT03572478?
The interventions under investigation include: Nivolumab (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03572478?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.